Results 151 to 160 of about 10,610 (205)

C1 inhibitor deficient hereditary angioedema is related to endothelial dysfunction in young adult and middle-aged patients. [PDF]

Clin Transl Allergy
Atay Sensoy GG, Baykız D, Toprak İD, Eyice Karabacak D, Bektas E, Unal D, Gelincik A, Demir S.   +7 more
europepmc   +1 more source

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials. [PDF]

EJHaem
Mesa RA, Talpaz M, Mazerolle F, Gorsh B, M'Hari M, Regnault A, Ellis C, Wang Z, Purser M, Liu T, Strouse B, Patnaik D.   +11 more
europepmc   +1 more source

Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer. [PDF]

BMC Pharmacol Toxicol
Irham LM, Adikusuma W, Afief AR, Khairi S, Chong R, Mufidah S, Satria RD, Mugiyanto E, Darmawi D, Amukti DP, Wirsahada BC, Philothra PT, Jaya I.   +12 more
europepmc   +1 more source

The prevalence and burden of heavy menstrual bleeding, and market access barriers of medical interventions with a focus on low- and middle-income countries: a scoping review. [PDF]

BMC Womens Health
Ammerdorffer A, Ferrillo O, Mills K, Guneratne T, Makama M, Romero L, McDougall ARA, Sothornwit J, Lumbiganon P, Bahamondes MV, Scott J, Chinery L, Bahamondes L, Vogel JP, Gülmezoglu AM.   +14 more
europepmc   +1 more source

Carbamazepine-induced aplastic anemia: A rare reported adverse drug reaction. [PDF]

Indian J Pharmacol
Kushwah A, Tomar APS, Shinde M, Acharya P.   +3 more
europepmc   +1 more source

The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies. [PDF]

Blood Lymphat Cancer
Reynolds SB, Komrokji R, Kuykendall AT.
europepmc   +1 more source

Aplastic anaemia with small paroxysmal nocturnal haemoglobinuria clones developing during osimertinib therapy for non-small cell lung cancer. [PDF]

Leuk Res Rep
Morimoto H, Katagiri S, Omori T, Otsuki S, Yoshizawa S, Furuya N, Fujimoto H, Takeuchi H, Gotoh A, Akahane D.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Danazol

Reactions Weekly, 2022
A comprehensive profile of danazol describing the nomenclatures, formulae, elemental composition, appearance, uses and applications is presented. The profile contains the method which was utilized for the preparation of the drug substance and its respective scheme is outlined.
  +5 more sources

Danazol

Annals of Internal Medicine, 1982
Danazol, approved 5 years ago for the treatment of pelvic endometriosis, has recently been approved for treating cystic disease of the breast. As the mechanisms of action of this drug are made clear, the clinical syndromes that can be treated by this impeded androgen have increased dramatically. Results of controlled prospective clinical studies on the
A E, Madanes, M, Farber
openaire   +4 more sources